138 related articles for article (PubMed ID: 31472048)
1. Analysis of serum cfDNA concentration and integrity before and after surgery in patients with lung cancer.
Fan Y; Shi M; Chen S; Ju G; Chen L; Lu H; Chen J; Zheng S
Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):56-63. PubMed ID: 31472048
[TBL] [Abstract][Full Text] [Related]
2. Serum cell-free DNA concentrations and integrity analysis of colorectal cancer patients before and after surgery.
Cao G; Xie Y; Jiang X; Tian X; Wang D; Sun Y
Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):44-51. PubMed ID: 31472046
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of cell-free DNA concentration and integrity in serum of gastric cancer patients before and after surgery.
Zhang X; Wu Z; Shen Q; Li R; Jiang X; Wu J; Li D; Wang D; Zou C; Zhong Y; Cheng X
Cell Mol Biol (Noisy-le-grand); 2019 Sep; 65(7):111-117. PubMed ID: 31880527
[TBL] [Abstract][Full Text] [Related]
4. Cell-free DNA as a biomarker for colorectal cancer: a retrospective analysis in patients before and after surgery.
Zhong Y; Zhou Q; Zhang Y; Zhou S; Zhang G; Jiang C; Zhang Z; Zhang X; Xu J; Jin C; Cao L; Chen L
Cell Mol Biol (Noisy-le-grand); 2020 May; 66(2):135-141. PubMed ID: 32415940
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of plasma cfDNA concentration and integrity in breast cancer patients.
Miao Y; Fan Y; Zhang L; Ma T; Li R
Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):64-72. PubMed ID: 31472049
[TBL] [Abstract][Full Text] [Related]
6. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
[TBL] [Abstract][Full Text] [Related]
7. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
8. Combinations of plasma cfDNA concentration, integrity and tumor markers are promising biomarkers for early diagnosis of non-small cell lung cancer.
Ren S; Zeng G; Yi Y; Liu L; Tu H; Chai T; Hu L
Heliyon; 2023 Oct; 9(10):e20851. PubMed ID: 37860559
[TBL] [Abstract][Full Text] [Related]
9. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
10. Investigation of Efficacy Evaluation Comparison of cfDNA and CEA in Colorectal Cancer.
Yu D; An G; Xu L
Clin Lab; 2016 Oct; 62(10):1947-1953. PubMed ID: 28164530
[TBL] [Abstract][Full Text] [Related]
11. The analysis of cell-free DNA concentrations and integrity in serum of initial and treated of lymphoma patients.
Wu J; Tang W; Huang L; Hou N; Wu J; Cheng X; Ma D; Qian P; Shen Q; Guo W; Peng W; Liu Y; Jiang C; Feng J
Clin Biochem; 2019 Jan; 63():59-65. PubMed ID: 30292543
[TBL] [Abstract][Full Text] [Related]
12. [Value of the concentration and integrity of serum cell-free DNA for the clinical diagnosis of esophageal carcinoma].
Qiu YW; Shen XJ; Jin CJ; Cao XJ; Ju SQ
Zhonghua Zhong Liu Za Zhi; 2018 Dec; 40(12):905-910. PubMed ID: 30605980
[No Abstract] [Full Text] [Related]
13. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules.
Szpechcinski A; Rudzinski P; Kupis W; Langfort R; Orlowski T; Chorostowska-Wynimko J
Cancer Lett; 2016 May; 374(2):202-7. PubMed ID: 26854716
[TBL] [Abstract][Full Text] [Related]
14. A quantitative analysis of the potential biomarkers of non-small cell lung cancer by circulating cell-free DNA.
Wei L; Wu W; Han L; Yu W; Du Y
Oncol Lett; 2018 Oct; 16(4):4353-4360. PubMed ID: 30250538
[TBL] [Abstract][Full Text] [Related]
15. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.
Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M
Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
[TBL] [Abstract][Full Text] [Related]
17. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
Zhou H; Wang XJ; Jiang X; Qian Z; Chen T; Hu Y; Chen ZH; Gao Y; Wang R; Ye WW; Cao WM
Breast Cancer Res Treat; 2019 Nov; 178(1):63-73. PubMed ID: 31364001
[TBL] [Abstract][Full Text] [Related]
18. [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
Liu YQ; Zhang HL; Gao WJ; Lan X; Yuan BJ; Zou JM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan; 26(1):34-8. PubMed ID: 18302890
[TBL] [Abstract][Full Text] [Related]
19. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
20. Circulating Cell Free DNA Integrity Index as a Biomarker for Response to Chemotherapy in Patients with Metastatic Colorectal Carcinoma.
Eskander NS; Mansour L; Abdelaal A; Saad E; Mohamed D
Asian Pac J Cancer Prev; 2022 Jan; 23(1):339-348. PubMed ID: 35092403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]